Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest Expenses (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Interest Expenses data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 8.79% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $11.8 million, down 12.83%, while the annual FY2025 figure was $11.8 million, 12.83% down from the prior year.
  • Interest Expenses reached $2.8 million in Q4 2025 per OCUL's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $4.2 million in Q4 2023 and bottomed at $1.7 million in Q2 2021.
  • Average Interest Expenses over 5 years is $2.5 million, with a median of $2.4 million recorded in 2023.
  • Peak YoY movement for Interest Expenses: soared 129.13% in 2024, then fell 26.34% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $1.7 million in 2021, then grew by 9.88% to $1.8 million in 2022, then soared by 124.86% to $4.2 million in 2023, then dropped by 25.17% to $3.1 million in 2024, then dropped by 8.79% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $2.8 million in Q4 2025, $3.0 million in Q3 2025, and $3.0 million in Q2 2025.